Interleukin-17 in transverse myelitis and multiple sclerosis

Jerome J. Graber, S. Rameeza Allie, Katherine M. Mullen, Melina V. Jones, Tongguang Wang, Chitra Krishnan, Adam I. Kaplin, Avi Nath, Douglas A. Kerr, Peter A. Calabresi

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.

Original languageEnglish (US)
Pages (from-to)124-132
Number of pages9
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - May 30 2008

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Interleukin-17 in transverse myelitis and multiple sclerosis'. Together they form a unique fingerprint.

Cite this